Volume 10, Number 2, February 2004

Interferon-ß1a and SARS Coronavirus Replication

Lisa E. Hensley,* Elizabeth A. Fritz,* Peter B. Jahrling,* Christopher L. Karp,† John W. Huggins,* and Thomas W. Geisbert*
*U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA; and Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

Figure 1. IFN-ß 1a inhibition of SARS-CoV replication in Vero E-6 cells. Top panels, Vero E6 cells were incubated in the absence (-▲-) or presence of IFN-ß 1a added 24 h before infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Bottom panels, Vero E6 cells were incubated in the absence (-▲-) or presence of IFN-ß 1a added 1 h after infection with the Tor2 (left) or Tor7 (right) isolate of SARS Co-V. Three concentrations of IFN-ß 1a were employed for both studies: 5,000 IU/mL (-□-), 50,000 IU/ml (-■-), 500,000 IU/mL (-■-) Samples of overlying media were collected at 24, 48, and 72 h postinoculation and analyzed by plaque assay on Vero E6 cells.

EID Home | Top of Page | Ahead-of-Print | Past Issues | Suggested Citation | EID Search | Contact Us | Accessibility | Privacy Policy Notice | CDC Home | CDC Search | Health Topics A-Z

This page last reviewed January 22, 2004

Emerging Infectious Diseases Journal
National Center for Infectious Diseases
Centers for Disease Control and Prevention